$2.63
6.07% yesterday
NYSE, Aug 01, 10:19 pm CET
ISIN
US92332V1070
Symbol
VTYX

Ventyx Biosciences Stock price

$2.63
+0.57 27.36% 1M
+0.76 40.64% 6M
+0.44 20.09% YTD
+0.39 17.41% 1Y
-11.66 81.60% 3Y
-18.39 87.49% 5Y
-18.39 87.49% 10Y
-18.39 87.49% 20Y
NYSE, Closing price Fri, Aug 01 2025
-0.17 6.07%
ISIN
US92332V1070
Symbol
VTYX
Industry

Key metrics

Basic
Market capitalization
$199.3m
Enterprise Value
$-29.6m
Net debt
positive
Cash
$228.8m
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.9
Financial Health
Equity Ratio
91.9%
Return on Equity
-53.2%
ROCE
-56.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-135.2m | $-116.0m
EBIT
$-136.8m | $-144.6m
Net Income
$-124.0m | $-137.0m
Free Cash Flow
$-109.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
34.7% | 21.2%
EBIT
34.0% | 2.6%
Net Income
35.6% | -1.4%
Free Cash Flow
40.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-1.5
Short interest
7.4%
Employees
73
Rev per Employee
$0.0
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Ventyx Biosciences forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a Ventyx Biosciences forecast:

Buy
73%
Hold
27%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
8% 8%
-
- Research and Development Expense 106 106
39% 39%
-
-135 -135
35% 35%
-
- Depreciation and Amortization 1.63 1.63
715% 715%
-
EBIT (Operating Income) EBIT -137 -137
34% 34%
-
Net Profit -124 -124
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
GlobeNewsWire
about 2 months ago
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Con...
Neutral
GlobeNewsWire
3 months ago
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025...
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 73
Founded 2018
Website ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today